| Title |
Survival in glioblastoma: a review on the impact of treatment modalities
|
|---|---|
| Published in |
Clinical and Translational Oncology, March 2016
|
| DOI | 10.1007/s12094-016-1497-x |
| Pubmed ID | |
| Authors |
P. D. Delgado-López, E. M. Corrales-García |
| Abstract |
Glioblastoma (GBM) is the most common and lethal tumor of the central nervous system. The natural history of treated GBM remains very poor with 5-year survival rates of 5 %. Survival has not significantly improved over the last decades. Currently, the best that can be offered is a modest 14-month overall median survival in patients undergoing maximum safe resection plus adjuvant chemoradiotherapy. Prognostic factors involved in survival include age, performance status, grade, specific markers (MGMT methylation, mutation of IDH1, IDH2 or TERT, 1p19q codeletion, overexpression of EGFR, etc.) and, likely, the extent of resection. Certain adjuncts to surgery, especially cortical mapping and 5-ALA fluorescence, favor higher rates of gross total resection with apparent positive impact on survival. Recurrent tumors can be offered re-intervention, participation in clinical trials, anti-angiogenic agent or local electric field therapy, without an evident impact on survival. Molecular-targeted therapies, immunotherapy and gene therapy are promising tools currently under research. |
Mendeley readers
The data shown below were compiled from readership statistics for 478 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Czechia | 1 | <1% |
| Unknown | 475 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 65 | 14% |
| Student > Ph. D. Student | 63 | 13% |
| Student > Bachelor | 63 | 13% |
| Researcher | 44 | 9% |
| Student > Doctoral Student | 37 | 8% |
| Other | 63 | 13% |
| Unknown | 143 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 96 | 20% |
| Biochemistry, Genetics and Molecular Biology | 71 | 15% |
| Agricultural and Biological Sciences | 37 | 8% |
| Neuroscience | 34 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 24 | 5% |
| Other | 61 | 13% |
| Unknown | 155 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2022.
All research outputs
#5,780,261
of 23,306,612 outputs
Outputs from Clinical and Translational Oncology
#241
of 1,336 outputs
Outputs of similar age
#79,894
of 301,362 outputs
Outputs of similar age from Clinical and Translational Oncology
#2
of 17 outputs
Altmetric has tracked 23,306,612 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,336 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,362 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.